Qualified candidates will be invited into the lab to conduct a short screening and study information session at the Clinical Addictions Research Laboratory at the University of Chicago. Screening and Randomization Participants will respond to advertisements and will undergo a brief phone screening to determine initial eligibility requirements. These will also be used at a 26-week follow-up by telephone with biochemical verification for CO in those reporting being smoke-free. Biochemical verification from breath tests for CO, as well as vital signs and weight, will be measured at each visit along with survey responses measuring smoking urge and withdrawal, negative affect, neurocognition, and alcohol and smoking behaviors. In this study, there will be 4 total in-person study visits over the trial (pre-quit, quit date, week 2 and week 12), ending 12 weeks after the quit date. While Chantix is approved for smoking cessation, it is not routinely given in practice for HDS patients
#CHANTIX FREE 30 DAY TRIAL 2020 PATCH#
This study will conduct a real-world clinic-based smoking cessation trial examining the augmentation strategy of Chantix (Varenicline Tartrate), nicotine patch, and behavioral counseling versus standard treatment of patch plus behavioral counseling only in heavy drinkers who smoke (HDS). Why Should I Register and Submit Results?.